Iran to soon start human trials for anti-coronavirus vaccine

Koohpayehzadeh urged the people to strictly follow health instructions to prevent the spread of the deadly disease.

Iranian medical scientists will soon start human trials for an anti-coronavirus vaccine after the stage of animal trials has passed, official news agency IRNA reported on Saturday.

"We hope these activities will bear the desired result in order to provide better preventive services for the people," Jalil Koohpayehzadeh, dean of Iran University of Medical Sciences and a member of Tehran anti-coronavirus committee, told IRNA.

As neither a working vaccine nor a specific drug has yet been produced against the COVID-19 infection, Koohpayehzadeh urged the people to strictly follow health instructions to prevent the spread of the deadly disease.

People should follow rules regarding the use of masks and social distancing and avoid gatherings and crowded places "as much as possible," he said.

Iran's confirmed COVID-19 cases hit 399,940 on Saturday, including 23,029 fatalities.

The country confirmed its first case of the virus on February 19.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel